Showing 1941-1950 of 2165 results for "".
- Qlaris Bio Developing Fixed-Dose Combination Therapy for the Treatment of Glaucomahttps://modernod.com/news/qlaris-bio-developing-fixed-dose-combination-therapy-for-the-treatment-of-glaucoma/2482844/Qlaris Bio announced it is developing a novel preservative-free, fixed-dose combination therapy that combines the company’s lead program, QLS-111, and latanoprost. The fixed-dose combination (QLS-111-FDC) is being developed as a treatment for p
- Navigate Patient Solutions Adds Ophthalmology Leaders to its Medical Advisory Boardhttps://modernod.com/news/navigate-patient-solutions-adds-ophthalmology-leaders-to-its-medical-advisory-board/2482835/Navigate Patient Solutions announced the addition of Vance Thompson, MD; David Cox, and Matthew P. Jensen to its Medical Advisory Board. Navigate is developing a patient engagement solution for ophthalmology. The startup partners with ophthal
- Atsena Therapeutics Granted FDA Orphan Drug Designation for Gene Therapy Targeting XLRShttps://modernod.com/news/atsena-therapeutics-granted-fda-orphan-drug-designation-for-gene-therapy-targeting-x-linked-retinoschisis/2482443/The FDA has granted Orphan Drug Designation to Atsena Therapeutics' product candidate, ATSN-201, which is designed for the treatment of X-linked retinoschisis (XLRS). This gene therapy utilizes the company’s AAV.SPR capsid technology, which enables targeted gene expression in the p
- J&J's Nipocalimab Significantly Improves Sjögren’s Disease Activity in a Phase 2 Studyhttps://modernod.com/news/jjs-nipocalimab-significantly-improves-sjogrens-disease-activity-in-a-phase-2-study/2482323/Johnson & Johnson announced that patients treated with nipocalimab demonstrated statistically significant (P=0.002) and clinically meaningful improvement in ClinESSDAIa score versus placebo at 24 weeks compared to baseline (primary endpoint) in the phase 2 DAHLIAS dose-rang
- EyePoint Fails to Reach Primary Efficacy Endpoint in Phase 2 Trial of Duravyu in NPDRhttps://modernod.com/news/eyepoint-fails-to-reach-primary-efficacy-endpoint-in-phase-2-trial-of-duravyu-in-npdr/2482265/EyePoint Pharmaceuticals announced topline results of its phase 2 PAVIA clinical trial evaluating Duravyu (vorolanib intravitreal insert), previously known as EYP-1901, in patients with non-proliferative diabetic retinopathy (NPDR). In the trial, Duravyu did not meet the pre-specified p
- Pantheon Vision Announces Two Pre-Submission Meetings With the FDAhttps://modernod.com/news/pantheon-vision-announces-two-pre-submission-meetings-with-the-fda/2482235/Pantheon Vision said it has completed two successful pre-submission meetings with the FDA. Pantheon Vision requested these early interactions with the FDA review team to obtain agency guidance on preclinical and clinical work supporting a premarket approval (PMA) submission. P
- Staar Surgical Celebrates Milestone and Unveils New EVO ICL Data at ASCRShttps://modernod.com/news/staar-surgical-celebrates-milestone-and-unveils-new-evo-icl-data-at-ascrs/2482194/At the ASCRS annual meeting in Boston, April 5-8, 2024, Staar Surgical will be celebrating a commercial milestone: 3 million lenses sold. Staar will be showcasing the clinical, practice and innovation advantages of the EVO ICL through a series of posters, presentations and educational p
- Results from Mont Blanc Phase 3 Trial of Nicox’s NCX 470 in Glaucoma Publishedhttps://modernod.com/news/results-from-mont-blanc-phase-3-trial-of-nicoxs-ncx-470-in-glaucoma-published/2482173/Nicox has published results results from the Mont Blanc phase 3 trial comparing NCX 470 to latanoprost in the lowering of IOP in patients with open-angle glaucoma or ocular hypertension in the American Journal of Ophthalmology. “We are pleased to see the p
- Glaukos Receives FDA Approval of iDose TR Intracameral Implanthttps://modernod.com/news/glaukos-receives-fda-approval-of-idose-tr-intracameral-implant/2482009/Glaukos received FDA approval for the iDose TR (travoprost intracameral implant 75 mcg), a first-of-its-kind, prostaglandin analog intracameral implant indicated for the reduction of IOP in patients with ocular hypertension or open-angle glaucoma. The iDose TR p
- FDA Approves Orasis Pharmaceuticals' Presbyopia Eye Drop Qlosihttps://modernod.com/news/fda-approves-orasis-pharmaceuticals-presbyopia-eye-drop-qlosi/2481896/Orasis Pharmaceuticals announced that the FDA has approved Qlosi (pilocarpine hydrochloride ophthalmic solution) 0.4% for the treatment of presbyopia in adults. Qlosi is expected to be commercially available in the US in the first half of 2024. Qlosi is a p